Overview Fundamentals API Earnings EOD API Sample Code Pricing

Incannex Healthcare Ltd ADR (IXHL NASDAQ) stock market data APIs

$2.175 0.01(0.5%) as of July 26, 2024
Price chart is built with Anychart

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Hea

Incannex Healthcare Ltd ADR Financial Data Overview

2.1666
2.175
-
2.195
2.12
0.8-12.68
38 108 K
17 643 K
661 K
2.266
Our easy-to-use no-coding solutions help you get the data effortlessly:

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'IXHL',
Type: 'Common Stock',
Name: 'Incannex Healthcare Ltd ADR',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG0125CL1D2',
ISIN: NULL,
CUSIP: NULL,
CIK: '1873875',
EmployerIdNumber: NULL,
FiscalYearEnd: 'June',
IPODate: '2022-03-02',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - Specialty & Generic',
HomeCategory: NULL,
IsDelisted: false,
}

Incannex Healthcare Ltd ADR Fundamental Data is available in our Financial Data APIs

  • Net Revenue 661 K
  • EBITDA -14 212 247
  • Earnings Per Share -1.27
  • Income Statements
  • Balance Sheets
  • Cash flows
Get sample
of Fundamental API Data

Get Incannex Healthcare Ltd ADR Earnings via APIs

  • Latest Release 2024-07-25
  • EPS/Forecast NaN

Get Incannex Healthcare Ltd ADR End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?
support@eodhistoricaldata.com